Medipost said that it has registered a patent for cultivating mesenchymal stem cells in China.
|Medipost headquarters in Seongnam, Gyeonggi Province.|
The patent, titled “method for culturing mesenchymal stem cells according to cell size,” relates to means of culturing mesenchymal stem cells with high therapeutic efficacy by adjusting the size and culturing environment of the cells.
Medipost said it plans to apply the patent to a new mesenchymal stem cell production process to produce highly effective treatments.
The company has also registered similar patents in Korea, Japan, Australia and the U.S.. It is developing the next pipeline through SMUP-Cell, a high-efficiency stem cell culture process, using the patented technologies.